Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST presepsin

Advances in Clinical Chemistry and Laboratory Medicine

Volumn , Issue , 2012, Pages 128-133

  Spanuth, Eberhard ^a   Ebelt, Henning ^b   Ivandic, Boris ^a   Werdan, Karl ^a  

^a Experimental Medicine GmbH   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85120389520     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (13)

1. Labeta MO, Durieux JJ, Fernandez N, Herrmann R, Ferrara P. Release from a human monocyte cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol 1993;23:2144-51.
2. Landmann R, Reber AM, Sansano S, Zimmerli W. Function of soluble CD14 in serum from patients with septic shock. J Infect Dis 1996;173:661-68.
3. Burgmann H, Winkler S, Locker GJ, et al. Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Cin Immunol Immunopathol 1996;80:307-10.
4. Herrmann W, Ecker D, Quast S, et al. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients. Clin Chem Lab Med 2000;38:41-46.
5. Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. Intensive Care Med 2007;33:1025-32.
6. European Patent 1571160 assigned to Mochida Pharmaceutical Co., LTD. Assay kit and antibody for human low molecular weight CD14. Patent granted May 10, 2005.
7. Shirakawa K, Furusako S, Endo S, et al. New diagnostic marker for sepsis: soluble CD14 subtype. Critical Care 2004;8(Suppl 1):P191doi: 10.1186/cc2658.
8. Yaegashi Y, Shirakawa K, Sato N, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005;11:234-38.
9. Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011, published online 12 May.
10. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
11. Ruiz-Alvarez MJ, Garcia-Valdecasa S. De Pablo R, et al. Diagnostic efficacy and prognostic value of serum procalcitonin concentrations in patients with suspected sepsis. J Intensive Care Med 2009;24:63-73.
12. Pencina MJ, D'Agostino RB, D'Agostino BJ, Vasan RS. Evaluating the added predictive ability of a new biomarker: from area under the ROC curve to classification and beyond. Stat Med 2008;27:157-72.
13. Tang BMP, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitoin for sepsis diagnosis in critical ill patients: systemic review and meta-analysis. Lancet Infect Dis 2007;7:210-17.